02 Feb2015
FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
SYDNEY, Jan. 29, 2015 /CNW/ – Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)